Navigating cellular immunotherapy options requires profound clarity rather than overwhelming confusion. The ImmunCell LC package at Dr Kims in South Korea provides a highly targeted autologous approach. Starting at approximately USD 3866 this protocol requires an initial blood draw followed by precise laboratory cultivation. Please remember that final eligibility and exact pricing depend entirely on your comprehensive medical assessment.
Quick Facts at a Glance
- Therapy Mechanism: Autologous Cytokine-Induced Killer (CIK) cell activation utilizing your own harvested immune cells.
- Primary Applications: Frequently utilized as an adjuvant protocol for hepatocellular carcinoma and specific solid tumors.
- Required Timeline: Approximately 14 to 21 days are necessary between the initial blood collection and the final intravenous infusion.
- Treatment Location: Administered under specialized clinical supervision at Dr Kims Stem Cell Clinic in Seoul.
- Medical Prerequisites: Requires recent oncology reports, comprehensive blood panels, and physician clearance prior to international travel.
- Post Procedure Care: Usually involves a brief period of outpatient monitoring to manage temporary cytokine-release symptoms.
How Much Does the ImmunCell LC Treatment Package Cost in South Korea?
Understanding the financial landscape of advanced cellular therapies helps patients plan their medical journeys effectively. South Korea has established a highly streamlined clinical infrastructure for immune cell cultivation, which often reflects in more accessible pricing structures compared to other global medical hubs.
| Medical Tourism Destination | Estimated Baseline Cost (USD) |
|---|---|
| South Korea | Starting at $3,866 |
| Japan | Starting at $8,500 |
| Germany | Starting at $12,000 |
| United States | Often restricted to clinical trials or exceeding $20,000 |
| Procedure Component | Estimated Cost | Component Description |
|---|---|---|
| Initial Consultation and Blood Draw | Included | In-person physician evaluation and autologous blood collection. |
| Specialized Cell Cultivation Phase | Included | Laboratory expansion and activation of immune effector cells. |
| ImmunCell LC 200 ml Infusion | Included | Intravenous delivery of the activated biological material. |
| Pre Travel Diagnostic Imaging | Excluded | Scans must be completed at home or billed independently. |
| Total Estimated Package Price | USD $3,866 | Final cost is strictly subject to individual clinical evaluation. |
What Is Included and Excluded in This Immunotherapy Package?
Typically Included
- Comprehensive specialist consultation in Seoul.
- Peripheral blood extraction procedure.
- GMP certified laboratory processing and cultivation.
- The finalized 200 ml intravenous infusion therapy.
- Basic nursing care and vital monitoring during the drip.
- Post infusion clinical review before clinic discharge.
Always Excluded
- International flights and local ground transportation.
- Hotel accommodations for the three week timeline.
- Independent diagnostic tests like MRI or CT scans.
- Additional medications to manage pre-existing conditions.
- Translation services if highly specialized interpretation is needed.
- Emergency hospitalization for unrelated health events.
How Does Autologous Cell Therapy Target Residual Cancer Cells?
The foundation of this treatment relies on the unique capabilities of Cytokine-Induced Killer cells. When a patient provides a blood sample, the laboratory isolates peripheral blood mononuclear cells. These foundational cells are then exposed to specific stimulating agents, fundamentally enhancing their natural capacity to recognize and eliminate abnormal tissue.
Unlike traditional treatments that indiscriminately attack rapidly dividing cells, this biological approach trains the immune system to target specific stress-induced ligands present on the surface of malignancies. This targeting mechanism is why the therapy is often utilized to address microscopic residual disease following surgery. The cultivation process ensures that millions of highly active effector cells are prepared for the final infusion.
The Three Stage Cellular Mechanism
- Extraction and Isolation: Clinicians draw peripheral blood to harvest dormant T-cells and Natural Killer cells.
- Cytokine Activation: In the laboratory, Interleukin-2 and anti-CD3 antibodies are introduced to force rapid cellular multiplication.
- Targeted Elimination: Once infused, the expanded cell population utilizes major histocompatibility complex pathways to locate and destroy malignant cells without harming healthy tissue.
Why Do Patients Choose Dr Kims Stem Cell Clinic in Seoul?
Navigating international medical care requires tremendous trust in the attending specialists and the clinical infrastructure. Dr Kim Hyun Soo has established a notable presence in South Korea regarding regenerative and immunological therapies. The clinic operates with a strict adherence to complex laboratory protocols necessary for handling living biological material.
For therapies involving cellular expansion, the distance between the patient, the clinic, and the processing laboratory must be highly synchronized. The facility in Seoul integrates clinical oncology perspectives with advanced cell handling capabilities, ensuring that international patients receive coordinated care from the moment their blood is drawn to the final infusion day.
Directed by Dr Kim Hyun Soo, prioritizing clinical safety and transparent patient communication.
Seamless coordination between the clinical diagnostic team and the cell cultivation laboratory.
Specialized experience managing the unique needs and timelines of international medical travelers.
What Are the Logistical Requirements for Blood Draw and Cultivation in Seoul?
The biological reality of the ImmunCell LC 200 ml treatment package dictates a rigid timeline that cannot be rushed. Cells require a minimum of two to three weeks to expand and mature in the laboratory environment. This timeline creates a unique logistical challenge for international patients traveling to South Korea.
Patients must decide how to manage this waiting period. Staying in Seoul for the entire duration requires securing long term accommodations and managing extended time away from home. Conversely, making two separate trips increases flight costs and physical travel fatigue. Understanding these two pathways is crucial for emotional and financial preparation.
| Option A: The Single Extended Stay | Option B: The Dual Trip Strategy |
|---|---|
| Day 1-3: Arrive in Seoul, undergo clinical consultation, and complete the peripheral blood draw. Day 4-18: Remain in South Korea. Patients rest at their hotel while laboratory cultivation occurs. Day 19-21: Return to the clinic for the 200 ml infusion, undergo observation, and fly home. |
Trip 1 (Days 1-4): Fly to Seoul strictly for the initial consultation and blood collection, then immediately fly home. Interim Period: Rest comfortably at home for two weeks while the cells are processed abroad. Trip 2 (Days 18-21): Fly back to South Korea specifically to receive the completed infusion, then depart. |
What Physical Reactions Could Occur Immediately After the Cell Infusion?
Introducing two hundred milliliters of highly activated immune cells into the bloodstream prompts an immediate systemic response. Because these cells are producing powerful cytokines, the body frequently reacts as if it is fighting off a sudden, aggressive infection. This is a recognized mechanism of action, not necessarily a complication.
Patients must be prepared for these transient side effects, which generally peak within the first twenty four hours following the procedure. The clinical team at Dr Kims is experienced in monitoring these expected reactions and providing supportive care to ensure patient comfort before medical clearance for travel is granted.
Expected Transient Responses
- Mild to moderate fever (often easily managed with antipyretics).
- Chills or sudden shivering directly following the drip.
- General fatigue and muscle aches resembling a viral illness.
- Temporary localized redness at the intravenous insertion site.
Rare but Monitored Events
- Severe hypotensive episodes requiring fluid resuscitation.
- Unexpected allergic responses or difficulty breathing.
- Prolonged fever lasting beyond forty eight hours post infusion.
Who Is an Ideal Candidate for ImmunCell LC Therapy?
Cellular immunotherapy is not a universal solution for all oncological diagnoses. Its efficacy relies heavily on the patient having a functional baseline immune system and a tumor type known to respond to immune modulation. Specifically, clinical data in South Korea heavily supports its use in hepatocellular carcinoma following surgical resection to address micro-metastases.
An ideal candidate must be carefully vetted by their primary oncologist prior to exploring medical travel. The patient must possess adequate liver and kidney function to safely process the cellular breakdown products and cytokine storm, and they must have an Eastern Cooperative Oncology Group performance status that allows for safe international transit.
Candidate Qualification Checklist
- Diagnosis: Confirmed presence of compatible solid tumors (frequently HCC or Glioblastoma).
- Timing: Often seeking adjuvant therapy post-surgery or post-ablation to minimize recurrence risks.
- Vitals: Stable cardiovascular health capable of withstanding potential transient fevers.
- Performance: Capable of independent travel and daily self-care activities (ECOG 0-1).
- Clearance: Explicit documented clearance from their home country treating oncologist.
How Might CIK Cell Infusions Interact With Other Ongoing Therapies?
One of the most critical aspects of planning cellular therapy is timing it correctly around standard oncology treatments. Because this package relies entirely on harvesting healthy, viable immune cells from the patient, administering it concurrently with therapies that deplete the immune system is highly counterproductive.
Cytotoxic chemotherapy regimens actively destroy rapidly dividing cells, including the very T-cells and Natural Killer cells required for this protocol. Therefore, strict washout periods are medically necessary. The clinic in South Korea will review current medication lists to determine the exact safety windows required before a successful blood draw can be attempted.
| Standard Therapy | Interaction Guidelines with Cellular Infusion |
|---|---|
| Systemic Chemotherapy | Requires a strict washout period. Harvesting cells during active chemotherapy yields non-viable or insufficient cellular counts. |
| Corticosteroids | Heavy immunosuppressants actively blunt the cytokine response, rendering the infused cells ineffective. Must be tapered prior. |
| Surgical Resection | Highly compatible. The therapy is frequently scheduled several weeks post-surgery to act as a targeted cleanup for residual cells. |
Frequently Asked Questions
What exactly is the ImmunCell LC therapy protocol?
ImmunCell LC is an autologous cytokine-induced killer cell therapy. It uses your own blood to harvest specific immune cells, which are then multiplied in a laboratory. These activated cells are infused back into your body to help identify and destroy residual cancer cells.
Is this immunotherapy a replacement for standard chemotherapy?
No, this cellular therapy is generally utilized as an adjuvant or complementary treatment. It is frequently administered after surgical resection or alongside standard oncology protocols to target microscopic disease and potentially lower recurrence rates.
Do I have to stay in South Korea during the entire cell cultivation period?
Patients have two primary logistical options. You can choose to stay in Seoul for the full two to three weeks required for laboratory cultivation. Alternatively, many international patients make a short initial trip for the blood draw, return home, and fly back to South Korea once the cells are ready for infusion.
How is the 200 ml cell dosage physically administered?
The activated immune cells are suspended in a 200 ml fluid solution and administered intravenously. The infusion process is straightforward and typically completed in an outpatient clinical setting under close medical observation.
Will my body potentially reject the infused immune cells?
Because this is an autologous therapy utilizing your own biological material, the risk of graft-versus-host disease or immune rejection is exceptionally low. Your body naturally recognizes the infused cells as its own.
How long does the actual infusion appointment take at the clinic?
The intravenous drip itself usually takes between one and two hours to complete. However, patients are typically monitored in the clinic for an additional few hours to ensure no immediate adverse reactions, such as fever, occur.
Can I fly home immediately after the procedure is finished?
Physicians generally recommend resting in Seoul for at least 24 to 48 hours following the infusion. This allows the clinical team to manage any temporary flu-like symptoms that sometimes accompany immunotherapy before you undertake a long international flight.
What makes Dr Kims clinic qualified for this specific therapy?
Dr Kim Hyun Soo is a recognized figure in South Korean regenerative and cellular medicine. His facility maintains specialized handling protocols, rigorous laboratory partnerships, and extensive experience managing international oncology patients seeking immune-based therapies.
Are there specific age restrictions for this immune treatment?
While there is no strict upper age limit, eligibility is heavily dependent on the patient's overall performance status and organ function. The attending physician must evaluate cardiovascular and hepatic health to ensure the patient can safely process the cytokine activity.
Why is this specific cellular therapy so prominent in South Korea?
South Korea has a progressive regulatory framework for advanced cellular therapies and a high prevalence of specific solid tumors like hepatocellular carcinoma. This environment has fostered extensive clinical data collection and refinement of the ImmunCell LC protocol within the country.
Take the Next Step in Your Care Journey
If you are exploring cellular immunotherapy options and want to know if the protocol in South Korea aligns with your current medical needs, our team is ready to help you coordinate a specialized review.
Request Free QuoteDisclaimer: The information provided on this page is intended for general informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or a guarantee of treatment outcomes, and you should always consult with a qualified healthcare provider regarding any specific medical conditions or treatment plans.
References
- National Cancer Institute. (n.d.). Cytokine-induced killer cells. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytokine-induced-killer-cells
- ClinicalTrials.gov. (2021). Adjuvant Immunotherapy With CIK Cells for Hepatocellular Carcinoma. https://clinicaltrials.gov/ct2/show/NCT00699816
- PubMed Central. (2019). Efficacy and Safety of Adjuvant Immunotherapy with Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678888/
- Korean Cancer Association. (2022). Guidelines for the Management of Hepatocellular Carcinoma. https://www.cancer.re.kr/
- National Institutes of Health. (2020). Advances in Cellular Immunotherapy for Solid Tumors. https://pubmed.ncbi.nlm.nih.gov/32145554/
.png)
.png)
Share this listing